Drug Profile


Alternative Names: E 0167; EA 0167; Glakay; KayTwo; Kaytwo® Syrup 0.2%; Menaquinone-4; MK 4; MQ 4; Vitamin K2

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Eisai Co Ltd
  • Class Calcium regulators; Naphthoquinones; Osteoporosis therapies; Vitamins
  • Mechanism of Action Osteogenesis stimulants; Prostaglandin receptor antagonists; Vitamin modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Postmenopausal osteoporosis; Vitamin deficiency
  • Discontinued Hepatocellular carcinoma

Most Recent Events

  • 25 May 2012 Registered for the prevention of Vitamin K deficiency haemorrrhage (0.2% syrup) in neonates and infants in Japan (PO)
  • 22 Oct 2004 Phase-II clinical trials in Hepatocellular carcinoma in Japan (unspecified route)
  • 01 Jul 1997 A study has been added to the Cancer pharmacodynamics section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top